阿瑪琳 AMRN 深 滬
交易中 10-30 10:17:06 美东时间
16.98
+0.170
+1.01%
華盛通- 最 高17.05
- 今 開16.56
- 成交量 4.36万股
- 最 低 16.18
- 昨 收 16.81
- 總市值 3.51亿
- 52周最高 20.90
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 7.08
- 委 比 73.91%
- 總股本 2068.28万
- 歷史最高 522.40
- 量 比 1.97
- 振 幅 5.18%
- 歷史最低 7.08
- 每 手 1
- 風險率 3.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amarin shares are trading lower. The company reported Q3 financial results.
Amarin shares are trading lower. The company reported Q3 financial results.
今天 02:22
Amarin Corp Q3 2025 Adj per ADS $0.19 Up From $(1.00) YoY, Sales $49.670M Beat $43.099M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.19 per share. This is a 119 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $49.670
10-29 19:17
Earnings Scheduled For October 29, 2025
Companies Reporting Before The Bell • OppFi (NYSE:OPFI) is expected to report q...
10-29 19:11
Earnings Outlook For Amarin Corp
Amarin Corp (NASDAQ:AMRN) is set to give its latest quarterly earnings report o...
10-29 05:01
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
Amneal Pharmaceuticals launched Brekiya® autoinjector, the first and only ready-to-use dihydroergotamine (DHE) autoinjector for treating migraines and cluster headaches in adults. Available exclusively through Walgreens and Sterling Specialty Pharmacies, Brekiya offers patients a convenient alternative to emergency room visits. Migraines affect 43 million Americans, and cluster headaches impact 300,000 individuals, with limited treatment options ...
10-27 12:00
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
Amarin Corporation plc applauds the FDA's decision to update fenofibrate labeling, emphasizing no cardiovascular benefits and increased risks when combined with statins. Clinical trials like FIELD, ACCORD Lipid, and PROMINENT show fenofibrates don't reduce cardiovascular events. Despite this, fenofibrates remain widely prescribed, with over 11 million U.S. prescriptions in 2023. Amarin倡导使用科学证据支持的疗法，如其产品VASCEPA，以帮助患者减少心血管事件风险。公司CEO Aaron Berg赞扬了FD...
10-27 12:00
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
Amarin Corporation plc announced it will report third quarter 2025 financial results and host a conference call on October 29, 2025. The press release will be issued pre-market, followed by the call at 8:00 a.m. ET. Participation details include telephone access via 877-545-0523 (US) or 973-528-0016 (international) with code 459510, and online via a webcast on www.amarincorp.com. A replay will be available through the same channels shortly after ...
10-15 12:00
HLS Therapeutics And Amarin To Present IPE And EPA Mechanistic Effects At Canadian Cardiovascular Congress 2025
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, in collaboration with its
10-14 20:48
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
Amarin Corporation plc and HLS Therapeutics are presenting scientific data on Icosapent Ethyl (IPE) and Eicosapentaenoic Acid (EPA) at the 2025 Canadian Cardiovascular Congress. The research highlights the clinical value of IPE for cardiometabolic conditions and explores EPA's effects on atherogenic lipoproteins and endothelial cells during inflammation when combined with a GLP-1 receptor agonist. Featured abstracts include studies on IPE's reduc...
10-14 12:00
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
Amneal Pharmaceuticals submitted a Biologics License Application (BLA) for a biosimilar to XOLAIR (omalizumab) to the FDA, developed by Kashiv BioSciences. XOLAIR, with U.S. annual sales of approximately $4.1 billion, is used for treating moderate to severe asthma, chronic rhinosinusitis, food allergies, and chronic urticaria. Amneal expects this submission to be a key growth driver, targeting the large U.S. market and planning additional biosimi...
09-26 12:00
